TAVR for Aortic Valve Disease
ConditionAortic Valve Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNanjing First Hospital, Nanjing Medical University
About this trial
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
Eligibility criteria
Qualifiers
Clinical diagnosis of severe aortic stenosis or aortic regurgitation
Patients undergo transcatheter aortic valve replacement
Disqualifiers
None
Trial design
Treatments tested in this trial
- transcatheter heart valve
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov